USPTO Examiner DIBRINO MARIANNE - Art Unit 1641

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19026296MRNA VACCINE ENCODING FUSION ANTIGEN AGAINST MPOX AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2January 2025April 2025Allow300YesNo
18408259CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS AND METHODS FOR TREATING MUC1* DISEASESJanuary 2024July 2024Abandon611NoNo
18372623FUSION PEPTIDE INHIBITORS OF HUMAN CORONAVIRUS 229ESeptember 2023February 2024Allow410YesNo
18372634FUSION PEPTIDE INHIBITORS OF HUMAN CORONAVIRUS 229ESeptember 2023July 2024Allow921NoNo
18198100FUSION PEPTIDE INHIBITORS OF HUMAN CORONAVIRUS 229EMay 2023November 2023Allow611YesNo
18089067NEUTROPHIL-BINDING PEPTIDESDecember 2022January 2024Allow1321YesNo
18053941Dry Powder Formulations of Thymic Stromal Lymphopoietin (TSLP)-Binding Antibodies and Methods of Use ThereofNovember 2022August 2024Allow2131NoNo
17937306ASSESSING AND TREATING AUTOIMMUNE ATAXIASeptember 2022October 2024Allow2521YesNo
17932600METHODS OF DETECTING ALLOANTIBODIES TO HLA CLASS II ANTIGENSSeptember 2022April 2025Allow3101YesNo
17861954Engineered HLA Alleles for Treating AutoimmunityJuly 2022December 2023Abandon1801YesNo
17861943Methods of Treating Autoimmunity With Engineered HLA ProteinsJuly 2022April 2024Abandon2111NoNo
17843243NOVEL IL2 AGONISTS AND METHODS OF USE THEREOFJune 2022February 2025Allow3251YesNo
17746835COMPOSITION FOR CULTURING NATURAL KILLER CELLS AND METHOD FOR PREPARING NATURAL KILLER CELLS BY USING SAMEMay 2022May 2025Allow3641YesNo
17454225POPULATION-BASED IMMUNOGENIC PEPTIDE IDENTIFICATION PLATFORMNovember 2021June 2025Abandon4301NoNo
17517805IMMUNOGENIC PEPTIDES FOR USE IN THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASES, AUTOIMMUNE DISEASES, IMMUNE RESPONSES TO ALLOFACTORS, ALLERGIC DISEASES, TUMORS, GRAFT REJECTION AND IMMUNE RESPONSES AGAINST VIRAL VECTORS USED FOR GENE THERAPY OR GENE VACCINATIONNovember 2021May 2025Abandon4201NoNo
17448020PERSONALISED IMMUNOGENIC PEPTIDE IDENTIFICATION PLATFORMSeptember 2021June 2025Abandon4401NoNo
17468095Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use ThereofSeptember 2021February 2025Abandon4101NoNo
17460104METHODS OF MAKING AND USING SOLUBLE MHC MOLECULESAugust 2021March 2025Abandon4301NoNo
17390702MODULATION OF ANTIGEN IMMUNOGENICITY BY DELETING EPITOPES RECOGNIZED BY NKT CELLSJuly 2021June 2025Abandon4601NoNo
17383265METHODS AND COMPOSITIONS FOR MODIFICATION OF HLAJuly 2021June 2025Abandon4711NoNo
17375985CIML NK cells and Methods ThereforJuly 2021August 2024Abandon3801NoNo
17191830Soluble Antibody Complexes for T Cell or NK Cell Activation and ExpansionMarch 2021March 2025Allow4821NoNo
17178525CLASS I MHC PHOSPHOPEPTIDES FOR CANCER IMMUNOTHERAPY AND DIAGNOSISFebruary 2021October 2024Abandon4401NoNo
17130192MODIFIED EPITOPES FOR BOOSTING CD4+ T-CELL RESPONSESDecember 2020March 2025Abandon5101NoNo
17247767ANTIBODIES AND METHODS OF USE THEREOFDecember 2020November 2024Abandon4701NoNo
17127627POLYCLONAL GAMMA DELTA T CELLS FOR IMMUNOTHERAPYDecember 2020January 2025Abandon4901NoNo
16973877ANTI-BCMA CAR ANTIBODIES, CONJUGATES, AND METHODS OF USEDecember 2020November 2024Allow4712NoNo
16953879Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironmentNovember 2020January 2024Allow3831YesNo
17099286PEPTIDESNovember 2020September 2024Abandon4601NoNo
17099267PEPTIDES DERIVED FROM PRORELAXIN H1 (RLN1)November 2020September 2024Abandon4601NoNo
17099242PEPTIDES DERIVED FROM ACHAETE-SCUTE HOMOLOG 2 (ASCL2), COMPLEXES COMPRISING SUCH PEPTIDES BOUND TO MHC MOLECULESNovember 2020September 2024Abandon4601NoNo
17087363PEPTIDESNovember 2020September 2024Abandon4701NoNo
17051410IMPROVED T-CELL THERAPY METHODOctober 2020April 2025Allow5411YesNo
17081821DRY POWDER FORMULATIONS OF THYMIC STROMAL LYMPHOPOIETIN (TSLP)-BINDING ANTIBODIES AND METHODS OF USE THEREOFOctober 2020October 2023Allow3621YesNo
15733755BLOOD BIOMARKER FOR EOSINOPHILIC GASTROINTESTINAL DISORDERSOctober 2020March 2025Allow5311YesNo
17069136ANTI-WT1/HLA-SPECIFIC ANTIBODIESOctober 2020September 2024Abandon4701NoNo
17017457PEPTIDES OF PAGE5September 2020April 2024Abandon4301NoNo
17017444CLAUDIN-6 PEPTIDESSeptember 2020March 2024Abandon4201NoNo
17013228PEPTIDESSeptember 2020March 2024Abandon4301NoNo
17010653PEPTIDESSeptember 2020March 2024Abandon4201NoNo
17009613ENHANCING T CELL ACTIVATION USING ALTERED MHC-PEPTIDE LIGANDSSeptember 2020October 2024Allow4910NoNo
17001847SYNTAC POLYPEPTIDES AND USES THEREOFAugust 2020December 2024Abandon5111NoNo
16998945PEPTIDES DERIVED FROM KALLIKREIN 4August 2020March 2024Abandon4301NoNo
16994399PEPTIDES FROM PIWIL1August 2020March 2024Abandon4301NoNo
16992821FRAGMENTS OF P97 AND USES THEREOFAugust 2020July 2024Abandon4701NoNo
16988431PEPTIDESAugust 2020March 2024Abandon4301NoNo
16988425PEPTIDESAugust 2020March 2024Abandon4301NoNo
16985797NK CELLS WITH AN INCREASED ANTIBODY-DEPENDENT CELLULAR TOXICITY (ADCC) AGAINST TUMORSAugust 2020August 2024Allow4911NoNo
16985061PEPTIDESAugust 2020February 2024Abandon4201NoNo
16985058PEPTIDES DERIVED FROM P ANTIGEN FAMILY MEMBER 2 (PAGE2)August 2020March 2024Abandon4301NoNo
16945701Lyme Disease-Associated T Cell Receptor-Related MethodsJuly 2020May 2024Allow4642YesNo
16938263PEPTIDESJuly 2020January 2024Abandon4201NoNo
16931304Soluble HLA class II complexes and methods of production and uses thereofJuly 2020April 2025Abandon5711NoNo
16928977ANTIBODIES TO MICA AND MICB PROTEINSJuly 2020January 2024Abandon4201NoNo
16959505MODIFIED MACROPHAGES AND MACROPHAGE PRECURSORS AND ASSOCIATED METHODSJuly 2020November 2024Abandon5211NoNo
16767392UBIQUITOUS ANTIGENS FOR TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASESMay 2020July 2024Allow4922YesNo
16847808EXPANDED NK CELLSApril 2020February 2024Abandon4601NoNo
16835761METHOD FOR ACTIVATING HELPER T CELLMarch 2020May 2025Allow6031YesYes
16811063METHOD FOR MASS PRODUCING NATURAL KILLER CELL AND USE OF NATURAL KILLER CELL OBTAINED BY THE METHOD AS ANTI-CANCER AGENTMarch 2020June 2025Allow6031YesNo
16796226Mononuclear Cell Derived NK CellsFebruary 2020October 2024Allow5521YesNo
16751638ACTIVATION OF iNKT CELLSJanuary 2020November 2023Abandon4610NoNo
16743849Antigen-Presenting Synthetic Surfaces, Covalently Functionalized Surfaces, Activated T Cells, and Uses ThereofJanuary 2020August 2024Abandon5511NoNo
16743940COMPOSITIONS, METHODS AND USES OF ALPHA 1-ANTITRYPSIN FOR TREATMENT OF GRAFT VERSUS HOST DISEASEJanuary 2020May 2024Abandon5211NoNo
16617622MMP-8 AS A MARKER FOR IDENTIFYING INFECTIOUS DISEASENovember 2019June 2025Allow6041YesNo
16685424COMPOUND COMPRISING AN AUTOANTIGENIC PEPTIDE AND A CARRIER WITH A MHC BINDING MOTIFNovember 2019October 2023Allow4721YesNo
16685765METHOD FOR THE ABSOLUTE QUANTIFICATION OF NATURALLY PROCESSED HLA-RESTRICTED CANCER PEPTIDESNovember 2019January 2024Allow5021YesNo
16610133IMPROVED LAMP CONSTRUCTS COMPRISING CANCER ANTIGENSNovember 2019March 2025Allow6031YesNo
16662808HLA-A3-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RASOctober 2019January 2025Abandon6042NoNo
16569691METHOD FOR HIGH THROUGHPUT PEPTIDE-MHC AFFINITY SCREENING FOR TCR LIGANDSSeptember 2019September 2024Allow6031YesNo
16492898Antigen Discovery for T Cell Receptors Isolated from Patient Tumors Recognizing Wild-Type Antigens and Potent Peptide MimotopesSeptember 2019December 2024Abandon6021NoNo
16548953NANOSCALE ARTIFICIAL ANTIGEN PRESENTING CELLSAugust 2019October 2023Allow5022NoNo
16510442NOVEL AND POWERFUL MHC-CLASS II PEPTIDES DERIVED FROM SURVIVINJuly 2019December 2023Allow5321NoNo
16507589BETA-2 MICROGLOBULIN-DEFICIENT CELLSJuly 2019August 2023Allow5021YesNo
16465675METHOD OF VALIDATING THE TRIGGERING OF AN IMMUNE RESPONSE TO A NEOEPITOPE OF A TUMOR WITH T-CELLSMay 2019April 2024Allow5941YesNo
16366320MODIFIED A1-A2 DOMAINS OF NON-NATURAL NKG2D LIGANDS THAT BIND NON-NATURAL NKG2D RECEPTORSMarch 2019July 2024Allow6031NoNo
16354605METHOD FOR PRODUCING NK CELL-ENRICHED BLOOD PREPARATIONMarch 2019November 2023Abandon5750YesNo
16228763METHOD FOR IN VITRO ACTIVATION AND/OR EXPANSION OF IMMUNE CELLSDecember 2018October 2023Allow5721YesNo
16312956MHC-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USESDecember 2018November 2023Abandon5921NoNo
16301381PEPTIDE EXCHANGE SYSTEM AND METHODNovember 2018March 2024Allow6022NoNo
16173150MULTISPECIFIC NK ENGAGER PROTEINOctober 2018November 2024Allow6041NoNo
16122562SIGNALING AND ANTIGEN-PRESENTING BIFUNCTIONAL RECEPTORS (SABR)September 2018September 2024Allow6061YesNo
16044866NATURAL KILLER CELLS WITH ENHANCED IMMUNE RESPONSEJuly 2018August 2024Allow6041YesNo
16015955MHC Multimers, Methods for Their Generation, Labeling and UseJune 2018May 2024Abandon6031NoYes
16008430REVERSIBLE PROTEIN MULTIMERS, METHODS FOR THEIR PRODUCTION AND USEJune 2018August 2024Allow6041YesYes
15780623MODIFIED CHIMERIC RECEPTORS AND RELATED COMPOSITIONS AND METHODSMay 2018July 2024Allow6052YesNo
15780624COMPOSITIONS AND METHODS FOR REDUCING IMMUNE RESPONSES AGAINST CHIMERIC ANTIGEN RECEPTORSMay 2018October 2023Allow6032NoNo
15773952IMMUNOTHERAPYMay 2018July 2023Allow6031YesNo
15750607IDENTIFICATION OF CLASS I MHC ASSOCIATED GLYCOPEPTIDES AS TARGETS FOR CANCER IMMUNOTHERAPYFebruary 2018October 2022Abandon5641NoNo
15807415RECOMBINANT pMHC CLASS II MOLECULESNovember 2017March 2022Abandon5261YesNo
15572137NANOPARTICLE COMPOSITIONS FOR SUSTAINED THERAPYNovember 2017November 2023Allow6061YesNo
15555613COMPOSITIONS AND METHODS FOR ENHANCING AN IMMUNE RESPONSESeptember 2017February 2024Allow6061YesNo
15536428ARTIFICIAL MULTI-ANTIGEN FUSION PROTEIN AND PREPARATION AND USE THEREOFJune 2017September 2023Allow6051YesNo
15436400STIMULATION OF THERAPEUTIC ANGIOGENESIS BY T REGULATORY CELLSFebruary 2017May 2019Allow2741YesNo
15027148Nanoparticle Based Artificial Antigen Presenting Cell Mediated Activation of NKT CellsApril 2016June 2023Allow6061YesNo
14973033MONOMERIC RECOMBINANT MHC MOLECULES USEFUL FOR MANIPULATION OF ANTIGEN-SPECIFIC T-CELLSDecember 2015November 2017Allow2321YesNo
14732145COMPOSITIONS AND METHODS USING RECOMBINANT MHC MOLECULES FOR THE TREATMENT OF STROKEJune 2015June 2016Allow1320NoNo
14695841PREPARATION OF ANTIBODY OR AN ANTIBODY FRAGMENT TARGETED IMMUNOLIPOSOMES FOR SYSTEMIC ADMINISTRATION OF THERAPEUTIC OR DIAGNOSTIC AGENTS AND USES THEREOFApril 2015June 2016Allow1410NoNo
14122937NOVEL ANTIGEN PEPTIDE AND USES THEREOFFebruary 2014December 2015Allow2441YesNo
13924275COMPOSITIONS AND METHODS USING RECOMBINANT MHC MOLECULES FOR THE TREATMENT OF STROKEJune 2013January 2015Allow1910NoNo
13731711MONOMERIC RECOMBINANT MHC MOLECULES USEFUL FOR MANIPULATION OF ANTIGEN-SPECIFIC T-CELLSDecember 2012September 2015Allow3201YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DIBRINO, MARIANNE.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
0
(0.0%)
Examiner Reversed
1
(100.0%)
Reversal Percentile
91.4%
Higher than average

What This Means

With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
14
Allowed After Appeal Filing
4
(28.6%)
Not Allowed After Appeal Filing
10
(71.4%)
Filing Benefit Percentile
38.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 28.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner DIBRINO, MARIANNE - Prosecution Strategy Guide

Executive Summary

Examiner DIBRINO, MARIANNE works in Art Unit 1641 and has examined 168 patent applications in our dataset. With an allowance rate of 72.0%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 48 months.

Allowance Patterns

Examiner DIBRINO, MARIANNE's allowance rate of 72.0% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by DIBRINO, MARIANNE receive 2.65 office actions before reaching final disposition. This places the examiner in the 89% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by DIBRINO, MARIANNE is 48 months. This places the examiner in the 1% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +53.9% benefit to allowance rate for applications examined by DIBRINO, MARIANNE. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 19.0% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 45.8% of cases where such amendments are filed. This entry rate is in the 64% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 92.3% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 91.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 71.2% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 8.3% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 18.2% of allowed cases (in the 92% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.